TYP Stock Overview
A clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tryptamine Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.045 |
| 52 Week High | AU$0.055 |
| 52 Week Low | AU$0.017 |
| Beta | 0 |
| 11 Month Change | 136.84% |
| 3 Month Change | 104.55% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 309.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| TYP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -8.2% | -11.8% | 1.5% |
| 1Y | n/a | 39.8% | 17.2% |
Return vs Industry: Insufficient data to determine how TYP performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TYP performed against the Australian Market.
Price Volatility
| TYP volatility | |
|---|---|
| TYP Average Weekly Movement | 20.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: TYP's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine TYP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Jason Carroll | www.tryptherapeutics.com |
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome.
Tryptamine Therapeutics Limited Fundamentals Summary
| TYP fundamental statistics | |
|---|---|
| Market cap | AU$57.44m |
| Earnings (TTM) | -AU$7.37m |
| Revenue (TTM) | AU$1.33m |
43.3x
P/S Ratio-7.8x
P/E RatioIs TYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYP income statement (TTM) | |
|---|---|
| Revenue | AU$1.33m |
| Cost of Revenue | AU$2.35m |
| Gross Profit | -AU$1.02m |
| Other Expenses | AU$6.35m |
| Earnings | -AU$7.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | -76.85% |
| Net Profit Margin | -555.37% |
| Debt/Equity Ratio | 3.5% |
How did TYP perform over the long term?
See historical performance and comparison